Literature DB >> 21911782

Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial.

Sharon Cresci1, Jun Wu, Michael A Province, John A Spertus, Michael Steffes, Janet B McGill, Edwin L Alderman, Maria Mori Brooks, Sheryl F Kelsey, Robert L Frye, Richard G Bach.   

Abstract

BACKGROUND: Coronary artery disease (CAD) is the major cause of death in patients with type 2 diabetes mellitus. Although demographic and clinical factors associated with extent of CAD in patients with diabetes mellitus have been described, genetic factors have not. We hypothesized that genetic variation in peroxisome proliferator-activated receptor (PPAR) pathway genes, important in diabetes mellitus and atherosclerosis, would be associated with extent of CAD in patients with diabetes mellitus. METHODS AND
RESULTS: We genotyped 1043 patients (702 white, 175 blacks) from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) genetic cohort for 3351 variants in 223 PPAR pathway genes using a custom targeted-genotyping array. Angiographic end points were determined by a core laboratory. In whites, a single variant (rs1503298) in TLL1 was significantly (P=5.5 × 10(-6)) associated with extent of CAD, defined as number of lesions with percent diameter stenosis ≥20%, after stringent Bonferroni correction for all 3351 single nucleotide polymorphisms. This association was validated in the diabetic subgroups of 2 independent cohorts, the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH) post-myocardial infarction registry and the prospective Family Heart Study (FHS) of individuals at risk for CAD. TLL1rs1503298 was also significantly associated with extent of severe CAD (≥70% diameter stenosis; P=3.7 × 10(-2)) and myocardial jeopardy index (P=8.7 × 10(-4)). In general linear regression modeling, TLL1rs1503298 explained more variance of extent of CAD than the previously determined clinical factors.
CONCLUSIONS: We identified a variant in a single PPAR pathway gene, TLL1, that is associated with the extent of CAD independently of clinical predictors, specifically in patients with type 2 diabetes mellitus and CAD. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00006305.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911782      PMCID: PMC3629972          DOI: 10.1161/CIRCULATIONAHA.111.029173

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  42 in total

1.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.

Authors:  Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson
Journal:  Am J Hum Genet       Date:  2003-12-15       Impact factor: 11.025

2.  Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype.

Authors:  Anna Csiszar; Mansoor Ahmad; Kira E Smith; Nazar Labinskyy; Qun Gao; Gabor Kaley; John G Edwards; Michael S Wolin; Zoltan Ungvari
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 3.  Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.

Authors:  M A Bouhlel; B Staels; G Chinetti-Gbaguidi
Journal:  J Intern Med       Date:  2007-11-27       Impact factor: 8.989

Review 4.  Vascular calcification: pathobiology of a multifaceted disease.

Authors:  Linda L Demer; Yin Tintut
Journal:  Circulation       Date:  2008-06-03       Impact factor: 29.690

5.  The final 10-year follow-up results from the BARI randomized trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  2007-04-02       Impact factor: 24.094

6.  Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D).

Authors:  Leonard Schwartz; Kevin E Kip; Edwin Alderman; Jiang Lu; Eric R Bates; Vankeepuram Srinivas; Richard G Bach; Lisa D Mighton; Frederick Feit; Spencer King; Robert L Frye
Journal:  Am J Cardiol       Date:  2009-01-12       Impact factor: 2.778

7.  Bone morphogenetic protein expression in human atherosclerotic lesions.

Authors:  K Boström; K E Watson; S Horn; C Wortham; I M Herman; L L Demer
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 8.  The PPAR trio: regulators of myocardial energy metabolism in health and disease.

Authors:  Jose A Madrazo; Daniel P Kelly
Journal:  J Mol Cell Cardiol       Date:  2008-04-04       Impact factor: 5.000

9.  Pioglitazone can downregulate bone morphogenetic protein-2 expression induced by high glucose in human umbilical vein endothelial cells.

Authors:  Ming Zhang; Sheng-hua Zhou; Sp Zhao; Xu-ping Li; Li-Ping Liu; Xiang-Qian Shen
Journal:  Pharmacology       Date:  2008-03-03       Impact factor: 2.547

10.  Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction.

Authors:  Koichi Kobayashi; Min Luo; Yue Zhang; David C Wilkes; Gaoxiang Ge; Thomas Grieskamp; Chikaomi Yamada; Ting-Chun Liu; Guorui Huang; Craig T Basson; Andreas Kispert; Daniel S Greenspan; Thomas N Sato
Journal:  Nat Cell Biol       Date:  2008-12-14       Impact factor: 28.824

View more
  15 in total

1.  Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.

Authors:  Sharon Cresci; Jeremiah P Depta; Petra A Lenzini; Allie Y Li; David E Lanfear; Michael A Province; John A Spertus; Richard G Bach
Journal:  Circ Cardiovasc Genet       Date:  2014-04-24

2.  A novel genetic marker of decreased inflammation and improved survival after acute myocardial infarction.

Authors:  Edward D Coverstone; Richard G Bach; LiShiun Chen; Laura J Bierut; Allie Y Li; Petra A Lenzini; Heidi C O'Neill; John A Spertus; Carmen C Sucharov; Jerry A Stitzel; Joel D Schilling; Sharon Cresci
Journal:  Basic Res Cardiol       Date:  2018-08-10       Impact factor: 17.165

3.  Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner.

Authors:  Sharon Cresci; Gerald W Dorn; Philip G Jones; Amber L Beitelshees; Allie Y Li; Petra A Lenzini; Michael A Province; John A Spertus; David E Lanfear
Journal:  J Am Coll Cardiol       Date:  2012-06-13       Impact factor: 24.094

Review 4.  Patient healthcare trajectory. An essential monitoring tool: a systematic review.

Authors:  Jessica Pinaire; Jérôme Azé; Sandra Bringay; Paul Landais
Journal:  Health Inf Sci Syst       Date:  2017-04-12

5.  CHRNA5 variant predicts smoking cessation in patients with acute myocardial infarction.

Authors:  Li-Shiun Chen; Richard G Bach; Petra A Lenzini; John A Spertus; Laura Jean Bierut; Sharon Cresci
Journal:  Nicotine Tob Res       Date:  2014-04-11       Impact factor: 4.244

6.  Chronic kidney disease: the "perfect storm" of cardiometabolic risk illuminates genetic diathesis in cardiovascular disease.

Authors:  Dwight A Towler
Journal:  J Am Coll Cardiol       Date:  2013-05-29       Impact factor: 24.094

7.  The CTGF gene -945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes.

Authors:  Sheila K Patel; Bryan Wai; Richard J Macisaac; Sharon Grant; Elena Velkoska; Michelle Ord; Sianna Panagiotopoulos; George Jerums; Piyush M Srivastava; Louise M Burrell
Journal:  Cardiovasc Diabetol       Date:  2012-04-26       Impact factor: 9.951

Review 8.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24

9.  Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.

Authors:  J P Depta; P A Lenzini; D E Lanfear; T Y Wang; J A Spertus; R G Bach; S Cresci
Journal:  Pharmacogenomics J       Date:  2014-07-08       Impact factor: 3.550

10.  Polymorphisms of the PPAR-γ (rs1801282) and Its Coactivator (rs8192673) Have a Minor Effect on Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus.

Authors:  Aleš Pleskovič; Marija Šantl Letonja; Andreja Cokan Vujkovac; Jovana Nikolajević Starćević; Danijel Petrovič
Journal:  PPAR Res       Date:  2016-02-02       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.